Aspira Pathlab & Diagnostics Ltd (ASPIRA) share fundamentals
Aspira Pathlab & Diagnostics Ltd is a micro-cap company in Health Care (Hospitals & Diagnostic Centres) with a market capitalisation of ₹144 crore. Here is where it stands on valuation, profitability, debt and growth as of 5 November 2026, and how it compares with the median Health Care company.
Financial health score
Out of 100, across five pillars of reported fundamentals.
What stands out
- Low debt (D/E 0.15x)
- Interest cover 1.1x — earnings barely cover interest
- PE of 2889.2x prices in a lot of growth
- Positive free cash flow and profitable
Aspira Pathlab & Diagnostics Ltd vs the Health Care median
| Metric | ASPIRA | Sector median | |
|---|---|---|---|
| PE ratioprice paid for each rupee of yearly profit | 2,889.2x | 26.11x | Weaker |
| Price to bookprice against the book value of assets | 10.64x | 2.93x | Weaker |
| EV / EBITDAbusiness value against operating profit | 73.11x | 18.12x | Weaker |
| Dividend yieldyearly dividend as a share of price | — | 0.4% | |
| Return on equityprofit on shareholders’ money | 0.4% | 10.6% | Weaker |
| ROCEprofit on all capital employed | 2.9% | 12.7% | Weaker |
| Net profit marginprofit kept from each rupee of sales | 0.2% | 7.7% | Weaker |
| Debt to equityborrowing against shareholders’ money | 0.15x | 0.2x | Better |
| Interest coveragehow many times profit covers interest | 1.13x | 7.86x | Weaker |
| Current ratioshort-term assets against short-term dues | 1.47x | 1.95x | Weaker |
| Revenue growth (1Y)change in sales over a year | 13.9% | 13.9% | In line |
| EPS growth (1Y)change in earnings per share over a year | -97.6% | 8% | Weaker |
| Promoter holdingshare owned by the founders or parent | 46.6% | 56.7% | Weaker |
| Promoter pledgepromoter shares pledged as loan security | 0% | 0% | In line |
| Betahow much it moves with the market | -0.81 | 0.88 | |
| 1-year returnshare price change over 52 weeks | 131.3% | -0.6% |
Tell DecideChart your amount, timeline and target return, and AI builds a full A4 report with risks, scenarios and worst cases. Your first report is free.
Other Health Care companies
Sun Pharmaceutical Industries LimitedSUNPHARMA · score 77.8
Divi's Laboratories LtdDIVISLAB · score 76
Torrent Pharmaceuticals LtdTORNTPHARM · score 63.7
Laurus Labs LtdLAURUSLABS · score 67.5
Apollo Hospitals Enterprise LimitedAPOLLOHOSP · score 59.5
Zydus Lifesciences LtdZYDUSLIFE · score 80
Dr. Reddy's Laboratories LimitedDRREDDY · score 67.9
Cipla LtdCIPLA · score 68.1
Mankind Pharma LtdMANKIND · score 57.4
Aurobindo Pharma LimitedAUROPHARMA · score 73.4
Lupin LimitedLUPIN · score 91.9
Max Healthcare Institute LimitedMAXHEALTH · score 59.9Frequently asked questions
What is the PE ratio of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd trades at a PE of 2,889.2x as of 5 November 2026, against a Health Care median of 26.11x. PE is the price paid for each rupee of yearly profit.
Is Aspira Pathlab & Diagnostics Ltd debt free?
No. Aspira Pathlab & Diagnostics Ltd has a debt-to-equity ratio of 0.15x, against a Health Care median of 0.2x.
What is the ROCE and ROE of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd has a return on capital employed of 2.9% and a return on equity of 0.4%. The Health Care medians are 12.7% and 10.6%.
What is the DecideChart health score of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd scores 33.4 out of 100, graded High risk. The score weighs profitability, debt, valuation, growth and governance from the company’s reported numbers. It is a research aid, not a recommendation.
Should I buy Aspira Pathlab & Diagnostics Ltd shares?
DecideChart does not give buy or sell tips and is not linked to SEBI, BSE or NSE. Use these numbers for your own research, compare Aspira Pathlab & Diagnostics Ltd with its Health Care peers, and consult a SEBI-registered adviser before investing.
Fundamentals from a public market-data screener, as of 5 November 2026. Figures can lag company filings. DecideChart is AI-based, not linked to SEBI, BSE or NSE, and does not give investment advice.